News

CRCHD seeks motivated scientists to serve as Program Directors in its Diversity Training Branch (DTB) and Integrated Networks Branch (INB). These Program Directors will manage and develop a portfolio of innovative grant-supported diversity training (DTB) and network-based initiatives (INB), and identify scientific opportunities to generate new knowledge supporting the NCI mission. The successful candidates will hold a Ph.D., M.D. or equivalent degree.

BioHealthInnovation invites you to join over 120 leading VCs, Corp VCs, Angel Investors and over 100
Top Innovators online at Venture Summit Virtual Connect being held on November 17th – 19 th 2020.
One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops
and an inspiring keynotes. Register now to confirm your spot: https://bit.ly/2DMyzYx & get an extra
20% off the Early Bird Rates with Discount Code: BIOHEALTHVIP .

Listen now via Apple https://apple.co/2RMiuoY, Google https://bit.ly/3iUXZCw, Spotify https://spoti.fi/32R5ll4, TuneIn https://bit.ly/33QE1m0, YouTube (Audio) https://bit.ly/367Ux47.

Dr. Mossman obtained her Ph.D. in herpes virology from the University of Liverpool, UK. Thereafter she conducted two postdoctoral fellowships in HIV vaccine research in the USA, first at Colorado State University, Fort Collins, and then at the University of Washington, Seattle. She spent 8 years within Corixa Corporation, a biotechnology company focusing on developing novel approaches to vaccines, including adjuvants, delivery strategies, and proprietary antigen candidates for infectious disease and cancer vaccines.  She joined GlaxoSmithKline Vaccines in 2006 and spent 10 years in Rixensart Belgium in the early development of infectious disease vaccines. More recently, she relocated to Maryland as part of the founding leadership team for the USA R&D headquarters for GSK Vaccines in Rockville, where she was initially heading up the Discovery effort. She is now Head of the Rockville R&D site and oversees a portfolio of vaccine candidates at all stages of development as well as driving key vaccine technologies, including mRNA and Adenovirus platforms. 

TENANT AMENITIES • Up to 21,400 RSF of office/lab suite available

• Divisible to 9,529 RSF and 11,871 RSF

• Conveniently located between Route 28 and Route 355 in Rockville, MD

• Proximate to other life science companies

• The proposed plans (attached) include heavily improved laboratory space • Emergency back-up power

• Ample surface parking

• Close proximity to Rockville Town Square, containing restaurants, retail, and more

Don’t miss your chance to be named the BioHealth Startup with the Most Commercial Potential at the BHCR Forum, win $10,000 and more!

Applications due: 9/30

Finalists notified by: 10/2

Mandatory presenter coaching for finalists: 10/7

Join fellow biotech leaders and is presented by the Association of University Research Parks, AstraZeneca, BioHealth Innovation, Children’s National Health System, Emergent BioSolutions, George Mason University, J.P. Morgan, Johns Hopkins University, Maryland Department of Commerce, Virginia Bio, and Wilson Sonsini Goodrich & Rosati, P.C.

Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

We are excited to bring you an exceptional line up of speakers to this virtual event!

This invitation-only event is free for executive level biotech leaders and is presented by the Association of University Research Parks, AstraZeneca, BioHealth Innovation, Children’s National Health System, Emergent BioSolutions, George Mason University, J.P. Morgan, Johns Hopkins University, Maryland Department of Commerce, Virginia Bio, and Wilson Sonsini Goodrich & Rosati, P.C.

Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

We are excited to bring you an exceptional line up of speakers to this virtual event!

*Please note that attendees’ name might be recorded if participating in the chat function during the event.

This invitation-only event is free for executive level biotech leaders and is presented by the Association of University Research Parks, AstraZeneca, BioHealth Innovation, Children’s National Health System, Emergent BioSolutions, George Mason University, J.P. Morgan, Johns Hopkins University, Maryland Department of Commerce, Virginia Bio, and Wilson Sonsini Goodrich & Rosati, P.C.

Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

We are excited to bring you an exceptional line up of speakers to this virtual event!

*Please note that attendees’ name might be recorded if participating in the chat function during the event.

BRUSSELS/PARIS (Reuters) – The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi SASY.PA and GSK GSK.L in its second such deal to secure supplies, as a deadline for joining the World Health Organization’s (WHO) vaccine purchase programme looms.